The phase 1 PERFORM study tested transplantation of fecal microbiota from a healthy donor along with immune checkpoint blockade in patients with previously untreated metastatic renal cell carcinoma. The treatment was safe. Encouraging signs of response to therapy were observed. Microbiome analyzes showed specific associations of donor taxa with toxicity. The study was published in Nature Medicine online on January 28, 2026.